Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma

Dr. Tim Greten: Looking forward to Immunotherapy 4.0 era of Hepatocellular Carcinoma

2024.02.01
Primary hepatocellular carcinoma is one of the most common malignant tumors in China, ranking second in the mortality rate of malignant tumors in the country. In recent years, significant progress has been made in HCC immunotherapy, bringing new hope to countless HCC patients. The evolution of HCC immunotherapy has gone through the era of PD-1/PD-L1 monotherapy 1.0, combined molecular targeted drug application 2.0, and further combined local treatment 3.0. With ongoing clinical research, the effectiveness of HCC immunotherapy has greatly improved. So, what will the era of HCC immunotherapy 4.0 look like? What challenges will we face next? At the recently concluded 17th International Liver Cancer Association (ILCA) Annual Meeting, Hepatology Digest had the honor of conducting an in-depth interview with Dr. Tim Greten from the National Institutes of Health and the National Cancer Institute's Cancer Research Center.
ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

ILCA 2023 | Liquid Biopsy Technology Based on Methylated SEPT9 Has the Potential to Establish a New Early Diagnosis System for Liver Cancer

2024.02.01
 Liver cancer is one of the malignant tumors with a high incidence and mortality rate in China. Most patients are clinically diagnosed late, with a high rate of postoperative recurrence and metastasis, which has become a significant factor affecting patient prognosis. There is an urgent need for technology that can effectively detect early liver cancer, monitor treatment effects in real-time, and prevent metastasis. Liquid biopsy technology has attracted attention in recent years as a new detection method. It is non-invasive, sensitive, and dynamic, showing promise in early tumor diagnosis, personalized medication guidance, and treatment monitoring. At the 17th International Liver Cancer Association Annual Meeting (ILCA 2023), Dr. Issei Saeki from School of Medicine of Yamaguchi University,Japan, reported a study (Abstract number: O-11) that assessed the clinical application value of liquid biopsy technology based on the methylated SEPT9 test for early diagnosis of non-viral hepatitis-related hepatocellular carcinoma (N-HCC).